Bayer continues to recognize Felix Hoffmann as aspirin's official inventor.
The right to use "Aspirin" in the United States (along with all other Bayer trademarks) was purchased from the U.S. government by Sterling Drug in 1918.
The most common cause of death during an aspirin overdose is noncardiogenic pulmonary edema.
Heroin was initially the more successful of the two painkillers and it was common belief that it was healthier than Aspirin.
Aspirin, as with many older drugs, has proven to be useful in many conditions.
Other countries (such as Canada and many countries in Europe) still consider "Aspirin" a protected trademark.
Aspirin overdose has serious consequences and is potentially lethal.
Arthur Eichengrьn claimed in 1949 that he planned and directed the synthesis of aspirin, while Hoffmann's role was restricted to the initial lab synthesis using Eichengrьn's process.
The name "aspirin" is composed of a- (from the acetyl group) -spir- (from the spiraea flower) and -in (a common ending for drugs at the time).
The side effect of this is that the ability of the blood in general to clot is reduced, and excessive bleeding may result from the use of aspirin.
Heart attacks are primarily caused by blood clots, and their reduction with the introduction of small amounts of aspirin has been seen to be an effective medical intervention.
Aspirin was the first discovered member of the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs), not all of which are salicylates, though they all have similar effects and a similar action mechanism.
Several hundred fatal overdoses of aspirin occur annually, but the vast majority of its uses are beneficial.
High doses of aspirin are also given immediately after an acute heart attack.
Salicylic acid is then acetylated using acetic anhydride, yielding aspirin and acetic acid as a byproduct.
On March 6, 1899, Bayer registered Aspirin as a trademark.
Aspirin is commercially synthesized using a two-step process.
Sterling was subsequently unable to prevent "Aspirin" from being ruled a genericized trademark in a U.S. federal court in 1921.
Low-dose, long-term aspirin irreversibly blocks formation of the lipid thromboxane A2 in platelets (type of blood cell involved in blood clotting).
Aspirin was originally sold as a powder and was an instant success; in 1915, Bayer introduced Aspirin tablets.
Fifty-two deaths involving single-ingredient aspirin were reported in the United States in the year 2000 (Litovitz 2001).
Formulations containing high concentrations of aspirin often smell of vinegar.
The brand name Aspirin was coined by the Bayer Company of Germany.
The platelets help form a plug that seals the opening in your blood vessel to stop bleeding. ... Then, a blood clot can quickly form and block the artery. This prevents blood flow to the heart and causes a heart attack. Aspirin therapy reduces the clumping action of platelets — possibly preventing a heart attack.